| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.05. | enVVeno Medical Corp reports results for the quarter ended in March - Earnings Summary | 2 | Reuters | ||
| 10.05. | enVVeno Medical Corp - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 09.05. | enVVeno Medical reports Q1 results | 1 | Seeking Alpha | ||
| 08.05. | enVVeno Medical Corporation: enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update | 343 | ACCESSWIRE | - Ended the quarter with $42.9 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025- Positive 11-month topline... ► Artikel lesen | |
| 08.05. | enVVeno Medical Corp - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 04.05. | enVVeno Medical Corp expected to post a loss of 40 cents a share - Earnings Preview | 1 | Reuters | ||
| 24.04. | enVVeno Medical Corporation: Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium | 233 | ACCESSWIRE | Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement = 3 Points) including:9.29 Points for... ► Artikel lesen | |
| 24.04. | enVVeno Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 16.04. | enVVeno Medical Corporation: New Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 | 345 | ACCESSWIRE | IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today... ► Artikel lesen | |
| 09.04. | enVVeno Medical Corporation: enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer | 351 | ACCESSWIRE | Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve®PMA application seeking FDA approval for the VenoValve on... ► Artikel lesen | |
| 16.03. | Envveno Medical CTO sells $51,837 in company stock | 1 | Investing.com | ||
| 15.03. | enVVeno Medical Corporation: enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity | 359 | ACCESSWIRE | Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, March 21st at 12:00 PM ETIRVINE, CA / ACCESSWIRE / March 15, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO)... ► Artikel lesen | |
| 06.03. | BeyondSpring, enVVeno Medical, Aptorum Group among healthcare movers | 4 | Seeking Alpha | ||
| 06.03. | enVVeno Medical Corporation: Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting | 269 | ACCESSWIRE | 97% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as Measured by the Revised Venous Clinical Severity Score (rVCSS))74% of the Study Patients Showing Clinical Meaningful Benefit... ► Artikel lesen | |
| 06.03. | enVVeno Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 01.03. | enVVeno Medical Corp reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 01.03. | enVVeno Medical reports FY results | 1 | Seeking Alpha | ||
| 29.02. | Recap: enVVeno Medical Q4 Earnings | 1 | Benzinga.com | ||
| 29.02. | enVVeno Medical Corp - 10-K, Annual Report | - | SEC Filings | ||
| 29.02. | enVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update | 447 | ACCESSWIRE | $46.4 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025Topline efficacy data for VenoValve® U.S. pivotal... ► Artikel lesen |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 7.298 |
| TUI | 5.650 |
| NEL | 5.270 |
| EVOTEC | 4.468 |
| NVIDIA | 3.894 |
| PLUG POWER | 2.515 |
| BAYER | 2.279 |
| BYD | 2.248 |
| BIONTECH | 1.822 |
| VOLKSWAGEN | 1.678 |
| RHEINMETALL | 1.620 |
| DEUTSCHE LUFTHANSA | 1.518 |
| SUPER MICRO COMPUTER | 1.439 |
| DEUTSCHE TELEKOM | 1.361 |
| ALLIANZ | 1.146 |
| AIXTRON SE | 1.139 |
| DEUTSCHE BANK | 1.001 |
| RWE | 987 |
| SIEMENS ENERGY | 977 |
| AMC ENTERTAINMENT | 969 |
| BASF | 964 |
| COMMERZBANK | 919 |
| JINKOSOLAR | 887 |
| TESLA | 877 |
| AMD | 870 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
